TABLE 2.
Treatment outcomes
| Non‐NKTCL | NKTCL | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (n = 60) | First line (n = 7) | Refractory (n = 33) | Relapsed (n = 20) | p‐value | Total (n = 15) | First line (n = 7) | Refractory (n = 6) | Relapsed (n = 2) | p‐value | |
| Median no. of cycles (range) | 3 (1–6) | 6 (4–6) | 3 (1–4) | 3 (1–5) | <.001 | 3 (1–7) | 4 (1–7) | 2 (1–3) | 4.5 (3–6) | .168 |
| Best response (%) | .149 | .640 | ||||||||
| CR | 23 (38.3) | 6 (85.7) | 9 (27.3) | 8 (40.0) | 7 (46.7) | 3 (42.9) | 2 (33.3) | 2 (100) | ||
| PR | 14 (23.3) | 1 (14.3) | 8 (24.2) | 5 (25.0) | 3 (20.0) | 2 (28.6) | 1 (16.7) | 0 (0) | ||
| SD | 4 (6.7) | 0 (0) | 4 (12.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| PD | 16 (26.7) | 0 (0) | 10 (30.3) | 6 (30.0) | 4 (26.7) | 1 (14.3) | 3 (50.0) | 0 (0) | ||
| Not done/unknown | 3 (5.0) | 0 (0) | 2 (6.1) | 1 (5.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| Progression‐free survival | ||||||||||
| No. of events/No. of patients | 49/60 | 1/7 | 30/33 | 18/20 | 12/15 | 5/7 | 6/6 | 1/2 | ||
| Median PFS, months (95% CI) |
4.6 (2.3, 7.4) |
Not reached |
3.4 (1.5, 5.3) |
4.4 (1.6, 23.9) |
.004 |
4.2 (1.0, 5.8) |
5.1 (1.0, UD) |
1.4 (0.6, UD) |
0.4 (0.4, UD) |
.393 |
|
6‐month PFS rate, % (95% CI) |
42.6 (29.9, 54.7) |
100 |
30.3 (15.9, 46.1) |
45.0 (23.1, 64.7) |
22.2 (5.5, 45.9) |
34.3 (4.8, 68.6) |
0 |
50.0 (0.6, 91.0) |
||
| Overall survival | ||||||||||
| No. of events/No. of patients | 38/60 | 0/7 | 26/33 | 12/20 | 11/15 | 5/7 | 5/6 | 1/2 | ||
| Median OS, months (95% CI) |
20.3 (10.8, 79.3) |
Not reached |
13.9 (6.9, 24.6) |
33.9 (3.9, UD) |
.024 |
6.7 (1.4, 33.1) |
8.2 (1.0, UD) |
5.2 (0.6, UD) |
33.1 (33.1, UD) |
.077 |
|
12‐month OS rate, % (95% CI) |
59.0 (45.3, 70.4) |
100 |
51.0 (33.0, 66.5) |
59.6 (35.1, 77.4) |
40.0 (14.9, 64.3) |
34.3 (4.8, 68.6) |
22.2 (1.0, 61.5) |
100 | ||
Abbreviations: CR, complete response; OS, overall survival; PD, progression of disease; PFS, progression free survival; PR, partial response; SD, stable disease; UD, undefined.